<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36462105</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1918</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical drug investigation</Title><ISOAbbreviation>Clin Drug Investig</ISOAbbreviation></Journal><ArticleTitle>Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>11</EndPage><MedlinePgn>1-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40261-022-01229-4</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">The efficacy and safety of edaravone for the treatment of amyotrophic lateral sclerosis (ALS) remain unclear. The aim of this meta-analysis was to&#xa0;provide evidence-based medical guidance and advice for the clinical application of edaravone in the treatment of ALS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">PubMed, Embase, Chinese Biomedical Literature Database (CBM), Cochrane Library and Web of Science were searched through 09 March 2022 for randomized controlled trials (RCTs) on the safety and efficacy of edaravone versus placebo during follow-up of patients with ALS. A summary of the outcome measures with GRADE was performed. This study was registered on PROSPERO (ID: CRD 42022319997).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Five RCTs with a total of 566 participants were included, and there was a significant difference (mean difference [MD] 1.33, 95% confidence interval [CI] 0.33-2.34; p&#xa0;=&#xa0;0.009) in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score between the treatment and placebo groups. The edaravone group had an increased grip strength (MD 0.26, 95% CI 0.03-0.49; p&#xa0;=&#xa0;0.03) and modified Norris Scale score (MD 2.81, 95% CI 1.18-4.43; p&#xa0;=&#xa0;0.0007). However, there were no significant differences between groups for the change in forced vital capacity (FVC)% (MD 0.55, 95% CI -&#xa0;3.15 to 4.24; p&#xa0;=&#xa0;0.77), pinch strength (MD 0.05, 95% CI -&#xa0;0.05 to 0.16; p&#xa0;=&#xa0;0.33) or Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) score (MD -&#xa0;4.76, 95% CI -&#xa0;9.56 to 0.03; p&#xa0;=&#xa0;0.05). The incidence of adverse events (AEs) (risk ratio [RR] 0.09, 95% CI 0.93-1.05; p&#xa0;=&#xa0;0.65), serious adverse events (SAEs) (RR 0.72, 95% CI 0.52-1.00; p&#xa0;=&#xa0;0.05) and the number of deaths (risk difference [RD] 0.00, 95% CI -&#xa0;0.02 to 0.03; p&#xa0;=&#xa0;0.83) were not statistically different from the placebo group. The quality of evidence was low only for SAEs, and the remaining outcome measures were of moderate quality.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared with placebo, edaravone may provide potential clinical benefits in the treatment of ALS and may not increase the number of AEs and deaths. However, due to the low-quality evidence of the included studies and the small sample size, more high-quality and high-standard research evidence is needed to confirm these results.</AbstractText><AbstractText Label="PROTOCOL REGISTRATION" NlmCategory="BACKGROUND">This study was registered on PROSPERO (ID: CRD 42022319997).</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Mengxia</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-9321-8986</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lingqun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Jingling</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Tianyu</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5299-847X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lianying</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5012-9716</Identifier><AffiliationInfo><Affiliation>Department of Radiology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Chunli</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4192-7139</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhuo</LastName><ForeName>Yudi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-3529-817X</Identifier><AffiliationInfo><Affiliation>Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fei</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6104-1541</Identifier><AffiliationInfo><Affiliation>Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China. dzmyyhouqin@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>No. 2019-JYB-TD-003</GrantID><Agency>Special Funds for Basic Scientific Research in Central Universities of China</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Drug Investig</MedlineTA><NlmUniqueID>9504817</NlmUniqueID><ISSNLinking>1173-2563</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>3</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36462105</ArticleId><ArticleId IdType="doi">10.1007/s40261-022-01229-4</ArticleId><ArticleId IdType="pii">10.1007/s40261-022-01229-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;72. https://doi.org/10.1056/NEJMra1603471 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zufir&#xed;a M, Gil-Bea FJ, Fern&#xe1;ndez-Torr&#xf3;n R, Poza JJ, Mu&#xf1;oz-Blanco JL, Rojas-Garc&#xed;a R, Riancho J, De Munain AL. ALS: a bucket of genes, environment, metabolism and unknown ingredients. Prog Neurobiol. 2016;142:104&#x2013;29. https://doi.org/10.1016/j.pneurobio.2016.05.004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2016.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. https://doi.org/10.1016/s1474-4422(17)30401-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(17)30401-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, Chi&#xf2; A, Rix-Brooks B, Van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15:1182&#x2013;94. https://doi.org/10.1016/s1474-4422(16)30199-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(16)30199-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur KC, Calvo A, Price TR, Geiger JT, Chi&#xf2; A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7:12408. https://doi.org/10.1038/ncomms12408 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, Van den Berg LH. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17085. https://doi.org/10.1038/nrdp.2017.85 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese EJ, Calabrese V, Giordano J. Demonstrated hormetic mechanisms putatively subserve riluzole-induced effects in neuroprotection against amyotrophic lateral sclerosis (ALS): implications for research and clinical practice. Ageing Res Rev. 2021;67: 101273. https://doi.org/10.1016/j.arr.2021.101273 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2021.101273</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ. Overview of current and emerging therapies for amytrophic lateral sclerosis. Am J Manag Care. 2020;26:S191&#x2013;7. https://doi.org/10.37765/ajmc.2020.88483 .</Citation><ArticleIdList><ArticleId IdType="doi">10.37765/ajmc.2020.88483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ralli M, Lambiase A, Artico M, De Vincentiis M, Greco A. Amyotrophic lateral sclerosis: autoimmune pathogenic mechanisms, clinical features, and therapeutic perspectives. Isr Med Assoc J. 2019;21:438&#x2013;43.</Citation></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018. Mayo Clin Proc. 2018;93:1617&#x2013;28. https://doi.org/10.1016/j.mayocp.2018.04.007 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2018.04.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, Li X, Li C, Tsang RCC, Chen Y, Ge Y, Gao Q. Effects of exercise in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2020;99:801&#x2013;10. https://doi.org/10.1097/phm.0000000000001419 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/phm.0000000000001419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadinejad F, M&#xf8;ller SG, Hashemzadeh-Chaleshtori M, Bidkhori G, Jami MS. Molecular mechanisms behind free radical scavengers function against oxidative stress. Antioxidants (Basel). 2017;6:51. https://doi.org/10.3390/antiox6030051 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox6030051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, Nakano S, Kusaka H. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448&#x2013;55. https://doi.org/10.1016/j.expneurol.2008.07.017 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Edaravone: a new drug approved for ALS. Cell. 2017;171:725. https://doi.org/10.1016/j.cell.2017.10.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19:185&#x2013;93. https://doi.org/10.1080/14737175.2019.1581610 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1581610</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, Petri S, G&#xfc;nther R, Wolf J, Hermann A, Prudlo J, Cordts I, Lingor P, L&#xf6;scher WN, Kohl Z, Hagenacker T, Ruckes C, Koch B, Spittel S, G&#xfc;nther K, Michels S, Dorst J, Meyer T, Ludolph AC. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79:121&#x2013;30. https://doi.org/10.1001/jamaneurol.2021.4893 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr&#xf3;bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https://doi.org/10.1136/bmj.n71 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16. https://doi.org/10.1186/1472-6947-7-16 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-7-16</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;9. https://doi.org/10.1080/146608200300079536 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards D, Morren JA, Pioro EP. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci. 2020;417: 117054. https://doi.org/10.1016/j.jns.2020.117054 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundh A, G&#xf8;tzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol. 2008;8:22. https://doi.org/10.1186/1471-2288-8-22 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-8-22</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, Treweek S, Mustafa RA, Vandvik PO, Meerpohl J, Guyatt GH, Sch&#xfc;nemann HJ. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. BMJ. 2016;353: i2089. https://doi.org/10.1136/bmj.i2089 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i2089</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610&#x2013;7. https://doi.org/10.3109/21678421.2014.959024 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone (MCI-186) ALS 18 Study Group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:40&#x2013;8. https://doi.org/10.1080/21678421.2017.1361441 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361441</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone (MCI-186) ALS 19 Study Group. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:55&#x2013;63. https://doi.org/10.1080/21678421.2017.1364269 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1364269</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;12. https://doi.org/10.1016/s1474-4422(17)30115-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group on Behalf of the Edaravone (MCI-186) ALS 17 Study Group. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:20&#x2013;31. https://doi.org/10.1080/21678421.2017.1362000 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1362000</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:414&#x2013;25. https://doi.org/10.3109/21678421.2016.1140786 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13&#x2013;21. https://doi.org/10.1016/s0022-510x(99)00210-5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, Song Z, Li X, Huiwang, Zeng Y, Qinwang, Meiqi, He J. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis. Neurol Sci. 2019;40:235&#x2013;41. https://doi.org/10.1007/s10072-018-3653-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-018-3653-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:241&#x2013;5. https://doi.org/10.1080/17482960600881870 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Clinical trial for amyotrophic lateral sclerosis with free radical scavenger, edaravone. Neurol Ther. 2003;20:557&#x2013;64.</Citation></Reference><Reference><Citation>Turnbull J. Is edaravone harmful? (A placebo is not a control). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:477&#x2013;82. https://doi.org/10.1080/21678421.2018.1517179 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1517179</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S, Maier A, Steinbach R, et al. Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol. 2022;79(2):121&#x2013;30. https://doi.org/10.1001/jamaneurol.2021.4893 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M, Tortorice K, Zacher J, et al. Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the Veterans Affairs Health Care System. JAMA Netw Open. 2020;3(10): e2014645. https://doi.org/10.1001/jamanetworkopen.2020.1464 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.1464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>